Aevum program
Aevum PT-141 Program
Bremelanotide for desire
From 99 USD / mo
Member price $84.15 · members save 15% (coming soon)
A clinician-led bremelanotide (PT-141) program for low sexual desire, with screening and follow-up.
Clinician-led program — billed monthly after intake.
- Central desire mechanism
- Clinician screening
- Follow-up monitoring
PT-141 acts on desire centrally rather than on blood flow — a different lever, and one that needs a clinical conversation first.
What the evidence says
Bremelanotide (Vyleesi) is FDA-approved for hypoactive sexual desire disorder in premenopausal women on the basis of the RECONNECT phase-3 trials (2019); other use is clinician-judged.
From the Physiome library
Independent, evidence-tiered reading on the science behind this product.
